BUSINESS AREA
Labtech
The Labtech business area provides products, solutions and services in fields such as diagnostics, biomedical research and laboratory analysis. The business area consists of two business units: Biomedical and Research and Diagnostics. The most important customer groups are hospital laboratories, academic research and pharmaceutical companies in Europe.
| Q4 | Q4 | ∆ | Full year | Full year | ∆ | |
| SEKm | 2025 | 2024 | % | 2025 | 2024 | % |
| Net sales | 1,073 | 1,141 | -6 | 3,953 | 3,797 | 4 |
| Organic growth, % | -3 | 6 | 5 | 3 | ||
| EBITA | 152 | 161 | -6 | 495 | 445 | 11 |
| EBITA margin, % | 14.1 | 14.1 | 12.5 | 11.7 |
FOURTH QUARTER
Net sales in Labtech for the quarter decreased by 6 percent to SEK 1,073m (1,141). Organic growth declined by 3 percent and exchange rate changes had a negative impact on net sales of 3 percent.
EBITA decreased by 6 percent to SEK 152m (161), corresponding to an EBITA margin of 14.1 percent (14.1). Exchange rate fluctuations had a negative impact on EBITA of 4 percent, corresponding to SEK 6m.
FULL YEAR
Labtech’s net sales for the financial year increased by 4 percent to SEK 3,953m (3,797), of which organic growth was 5 percent and acquired growth was 1 percent. Exchange rate changes had a negative impact on net sales of 2 percent.
EBITA increased by 11 percent to SEK 495m (445), corresponding to an EBITA margin of 12.5 percent (11.7). Exchange rate changes had a negative impact on EBITA of 3 percent, corresponding to SEK 13m.
Net sales in Labtech declined slightly in the quarter, partly due to lower instrument sales than in the previous year, when many tenders took place. Sales of consumables related to these tenders continue to contribute positively to both growth and margins.
A more cautious approach regarding investments has been noted among certain pharmaceutical customers during the quarter.
Demand was strong in Central and Eastern Europe during the third quarter, and this positive trend continued in the fourth quarter. Advanced products, for example in gene sequencing, continue to drive growth with high margins.
Margins were maintained at the same high level as in the strong fourth quarter of the previous year.
On a full-year basis, sales in Labtech grew organically by 5 percent, which is significantly higher than market growth, and the EBITA margin strengthened to 12.5 percent compared with 11.7 percent in the previous year.